BIO Spring 2016: Immunovia's quest to make early-stage pancreatic diagnosis a clinical reality

The Swedish company is working to build an evidence base for its serum-based cancer diagnostic in the U.S. market. 

By Nicole Gray • April 6, 2016

Remicade copy clears FDA, becomes second biosim to win approval in U.S.

The biosimilar version of J&J's blockbuster inflammatory drug will be co-marketed by the Korean drugmaker Celltrion and Pfizer as Inflectra.

By Ned Pagliarulo • April 5, 2016

Explore the Trendline➔

Commercialization

New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

By BioPharma Dive staff

Analysis shows pharma companies aggressively increased prices on widely used drugs

Four of the top 10 drugs more than doubled in price between 2011 and 2014, according to the report. 

By Nicole Gray • April 5, 2016

Report: Valeant cuts sales force for female libido drug

Addyi has been a sales disappointment since its launch in October.  

By Ned Pagliarulo • April 4, 2016

Samsung Bioepis' biosim of Remicade clears regulatory hurdle in EU

Samsung's version would be the second copy of Remicade in the EU, if approved. South Korea-based Celltrion previously won approval for its drug Remsima. 

By Ned Pagliarulo • April 1, 2016

GSK won't file drug patents in low-income countries

Additionally, the drugmaker will offer 10-year licenses for generic versions of its medicines in lower middle income countries. 

By Ned Pagliarulo • March 31, 2016

Could long-term "mortgages" help patients fund short-term curative treatments?

A recent article proposed long-term installment loans as a potential solution for increasing access to pricey, but extremely effective drugs like Harvoni. 

By Nicole Gray • March 30, 2016

Xenoport sells US rights to psoriasis drug to Dr. Reddy's

CA-based Xenoport has struggled with mixed clinical trial results for its psoriasis candidate and financial woes that led to layoffs. 

By Nicole Gray • March 30, 2016

Denmark-based Lundbeck emerges as top-ranked company in survey of US patient groups

It fared particularly well in measures of patient-centricity and transparency. 

By Nicole Gray • March 30, 2016

In reversal, FDA denies cognitive dysfunction label expansion for Brintellix

An advisory committee had previously recommended approval for the new indication in February. 

By Nicole Gray • March 30, 2016

US gov demands more information from Novartis on purported kickbacks

The drugmaker is accused of treating doctors to expensive meals in return for prescribing Novartis' drugs. 

By Nicole Gray • March 28, 2016

Spending on Vertex's Kalydeco consumed 86% of Scottish rare disease fund's budget

The special government fund reportedly spent £18.6 million on the cystic fibrosis drug between 2013 and 2014.

By Ned Pagliarulo • March 28, 2016

Valeant doubled price of physician-assisted suicide drug

The drugmaker increased the price of the drug shortly after acquiring it, and one month after lawmakers in California proposed aid-in-dying legislation.   

By Nicole Gray • March 24, 2016

Brexit could complicate marketing status of drugs, new licenses

The European pharma industry has strongly opposed a U.K. exit from the E.U.  The U.K. votes in a June 23 referendum whether to stay or leave. 

By Nicole Gray • March 23, 2016

Why ViiV Healthcare leads the pharma industry in corporate reputation

The HIV company has come in first the past three years in a global survey asking the views of more than 1,000 patient groups.

By Nicole Gray • March 22, 2016

Former Turing exec to Senate panel: We warned Shkreli about Daraprim price hike

Turing's former general counsel testified the price increase was "not justified" by any R&D expenditure. 

By Nicole Gray • March 18, 2016

Despite promising clinical results, uptake challenges continue for Novartis' Entresto

Sales of the heart failure med have disappointed since its launch in July 2015. 

By Nicole Gray • March 17, 2016

Valeant acquires Orexigen's obesity drug, stock continues its slide

The company announced the acquisition of European rights to Mysimba the same day it revealed significantly downgraded sales forecasts. 

By Nicole Gray • March 16, 2016

CDC issues new guidelines for prescribing opioids

The guidelines aim to reduce over-prescribing of opioid painkillers as rates of abuse and overdose deaths have steadily increased in the U.S. 

By Nicole Gray • March 16, 2016

Survey: Pharma advertising works—especially with millennials

Millennials proved more likely than other generations to visit a pharmaceutical company’s website after seeing pharma-related advertising. 

By Nicole Gray • March 16, 2016

Express Scripts: Growth in overall U.S. drug spending slowed in 2015

But prices for branded prescription drugs have doubled since 2011, increasing 16.2% in 2015 alone. 

By Ned Pagliarulo • March 15, 2016

Sanders proposes cash prize for development of lower-priced AIDS drugs

Rather than give companies patent exclusivity, Sander's plan would open the door to generic competition immediately. The original developer would be rewarded annually through a $3 billion cash prize program. 

By Nicole Gray • March 15, 2016

Indian Health Ministry bans nearly 350 combo drugs

Fixed dose combinations have proliferated in India, making up nearly half of all drugs on the market in 2014 despite many being unapproved nationwide. 

By Nicole Gray • March 14, 2016

Boehringer turns to 'red fish' for Pradaxa boost

The FDA recently approved an "antidote" drug specifically for use with Pradaxa to counteract bleeding episodes—an aspect Boehringer is highlighting in its new marketing campaign. 

By Nicole Gray • March 14, 2016

Doctors Without Borders moves to block Pfizer patent in India

Pfizer filed in India to patent its Prevnar vaccine for pneumonia, which pulled in over $6 billion in global sales last year. 

By Ned Pagliarulo • March 11, 2016